Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASGNMSF -2.66%92 Receivables Turnover is 0.86 as of Mar. 2026. GuruFocus rates GNMSF with a GF Score™ of 92/100 and a GF Value™ of $355.30 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 841 Biotechnology companies, Genmab AS ranks worse than 65.4% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Genmab AS's Revenue for the
three
months ended in Mar. 2026 was $896 Mil. Genmab AS's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1,040 Mil.
Hence, Genmab AS's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.86.
Genmab AS (OTCPK:GNMSF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Genmab AS Receivables Turnover Related Terms
Genmab AS Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Genmab AS's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNMSF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Genmab AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Genmab AS's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (GNMSF) has a Receivables Turnover of 0.86 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genmab AS and its competitors. According to the industry distribution chart, Genmab AS ranks #550 out of 841 companies in the Biotechnology industry, placing it in the top 65.4%.
Is Genmab AS's Receivables Turnover too high?
Genmab AS's current Receivables Turnover is 0.86. The Biotechnology industry median Receivables Turnover is 5.29. Genmab AS's value of 0.86 is 83.7% below this industry median. Based on the distribution chart, Genmab AS ranks #550 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #550 out of 841 companies for Receivables Turnover. This places Genmab AS in the lower half of its industry. The industry median Receivables Turnover is 5.29. Genmab AS's value of 0.86 is 83.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Receivables Turnover of 0.86 is 83.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Receivables Turnover is 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $355.30, compared to a current price of $274.50 — trading 22.7% below its estimated fair value. The current Receivables Turnover is 0.86 and 83.7% below the Biotechnology industry median of 5.29. Genmab AS's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Receivables Turnover is 0.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (GNMSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of $274.50 is trading 22.7% below its estimated GF Value™ of $355.30.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for GNMSF:
Receivables Turnover: 0.86
GF Value™: $355.30 vs. price of $274.50 (22.7% below fair value)
Industry Position: 83.7% below the Biotechnology median (#550 of 841)
No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score
Get the complete analysis for GNMSF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNMSF has been successfully added to your 
